Search results
Results from the WOW.Com Content Network
Phenobarbital, also known as phenobarbitone or phenobarb, sold under the brand name Luminal among others, is a medication of the barbiturate type. [6] It is recommended by the World Health Organization (WHO) for the treatment of certain types of epilepsy in developing countries . [ 8 ]
Luminal (phenobarbital) – a barbiturate with sedative and hypnotic properties; R. Remeron (mirtazapine) – an atypical antidepressant, used off-label as a sleep aid;
Tedral is also composed of phenobarbital, therefore, it is contraindicated for individuals with: [8] [5] [20] Hypersensitivity to phenobarbital, barbiturates or any component of the formulation. A history/manifest or latent porphyria; Liver impairment; Nephritic syndrome (at high dose) A history of sedative-hypnotic drug addiction
Phenobarbital reduces the half-life to 4.8 ± 1.3 and increases the clearance by almost 109%. [66] It also interferes with the metabolism of dexamethasone , a synthetic steroid hormone, to the point where its withdrawal from the regimen of a 14-year-old living in the United Kingdom made her hypercortisolemic . [ 67 ]
There were shortage reports related to phenobarbital from 18 July 2017 to 1 March 2018, disrupting the flow of the production process with quality, time and cost control. With all the factors considered, on 6 June 2018, Bellergal was discontinued by Paladin Labs due to its raw material availability and limited efficacy; while the remaining ...
Only the phenobarbital group demonstrated a significant change in pain type compared to belladonna alkaloids at the end of the study with an approximate 48% response rate. Patients on Donnatal® tablets, belladonna alkaloids, and placebo all had non-significant (p > 0.149) shifts to dull pain, 39.5%, 52.3%, and 40.4%, respectively compared to ...
Barbital, then called "Veronal", was first synthesized in 1902 by German chemists Emil Fischer and Joseph von Mering, who published their discovery in 1903. [2] Barbital was prepared by condensing diethylmalonic ester with urea in the presence of sodium ethoxide, or by adding at least two molar equivalents of ethyl iodide to the silver salt of malonylurea (barbituric acid) or possibly to a ...
Alfred Hauptmann (August 29, 1881, in Gleiwitz, Upper Silesia – April 5, 1948, in Boston, Massachusetts) was a German-Jewish psychiatrist and neurologist. [1]His most important contribution remained the article written in 1912 on the effectiveness of the phenobarbital as an anti-epileptic.